Analyst Price Targets — ALMS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 19, 2026 11:56 am | — | Chardan Capital | $40.00 | $21.09 | TheFly | Alumis price target raised to $40 from $38 at Chardan |
| May 15, 2026 12:20 pm | Terence Flynn | Morgan Stanley | $39.00 | $23.82 | TheFly | Alumis price target raised to $39 from $38 at Morgan Stanley |
| May 15, 2026 10:55 am | — | Wells Fargo | $51.00 | $24.63 | TheFly | Alumis price target raised to $51 from $49 at Wells Fargo |
| May 15, 2026 10:27 am | Yatin Suneja | Guggenheim | $34.00 | $24.63 | TheFly | Alumis price target raised to $34 from $32 at Guggenheim |
| May 15, 2026 10:09 am | Mitchell Kapoor | H.C. Wainwright | $25.00 | $24.63 | TheFly | Alumis downgraded to Neutral from Buy at H.C. Wainwright |
| March 10, 2026 8:05 pm | Christopher Raymond | Raymond James | $46.00 | $28.10 | StreetInsider | Raymond James Starts Alumis Inc (ALMS) at Strong Buy |
| January 21, 2026 9:36 am | — | Chardan Capital | $37.00 | $26.06 | TheFly | Alumis initiated with a Buy at Chardan |
| January 21, 2026 8:52 am | Janani Sundararajan | Loop Capital Markets | $37.00 | $26.06 | StreetInsider | Chardan Capital Markets Starts Alumis Inc (ALMS) at Buy |
| January 9, 2026 11:11 am | — | H.C. Wainwright | $40.00 | $18.18 | TheFly | Alumis price target raised to $40 from $20 at H.C. Wainwright |
| January 7, 2026 11:43 am | — | Morgan Stanley | $33.00 | $16.23 | TheFly | Alumis price target raised to $33 from $22 at Morgan Stanley |
Latest News for ALMS
Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline of 86% from the average daily volume of 2,138,687 shares. The stock had previously closed at $27.23. Wall Street Analysts
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and…
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALMS.
U.S. House Trading
No House trades found for ALMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.